The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Ghassan K. Abou-Alfa
Consultant or Advisory Role - Bayer
Research Funding - Amgen; Bayer
Jean-Frédéric Blanc
No relevant relationships to disclose
Steven Miles
No relevant relationships to disclose
Tom M. Ganten
No relevant relationships to disclose
Jorg Trojan
Honoraria - Amgen; Bayer
Jonathan S. Cebon
No relevant relationships to disclose
Andre K. D. Liem
No relevant relationships to disclose
Lara Rachel Lipton
No relevant relationships to disclose
Charu Gupta
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Benjamin Wu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jason B. Litten
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Other Remuneration - Amgen
Leonard Saltz
Research Funding - Amgen; Bayer